摘要
目的研究脓毒症合并早期急性肾损伤(AKI)患者治疗前后可溶性髓系细胞触发受体-1(sTREM-1)、血管生成素-2(Ang-2)及降钙素原(PCT)水平变化及其与预后相关性分析。方法将2015年6月—2018年1月我院收治的98例ICU脓毒症患者,根据其是否发展为AKI分为脓毒症合并AKI组35例和未合并AKI组63例;依据脓毒症合并AKI患者的病情发展分为恶化组23例和好转组12例,检测各组血清sTREM-1、Ang-2及PCT水平变化,ROC曲线分析其与脓毒症AKI恶化的相关性。结果脓毒症合并AKI组血清中sTREM-1、Ang-2、PCT水平高于未合并AKI组(P<0.01)。脓毒症合并AKI组治疗后血清中上述指标低于治疗前,恶化组上述指标水平高于好转组(P<0.01)。ROC曲线分析显示血清中sTREM-1、Ang-2、PCT与脓毒症合并AKI恶化相关性的曲线下面积分别为0.76、0.73、0.81。结论脓毒症合并早期AKI治疗后血清中较高水平的sTREM-1、Ang-2、PCT与患者的不良预后密切相关。
Objective To study changes of levels of soluble triggering receptor expressed on myeloid cell-1(sTREM-1),angiopoietin-2(Ang-2)and procalcitonin(PCT)before and after treatment in patients with sepsis complicated by early acute kidney injury(AKI)and their correlations with prognosis.Methods A total of 98 patients with ICU sepsis admitted during June 2015 and January 2018 were divided into sepsis AKI group(n=35)and sepsis non-AKI patient group(n=63)according to whether or not having AKI.The sepsis AKI group was divided into deterioration subgroup(n=23)and improvement subgroup(n=12)according to disease development.Changes of serum sTREM-1,Ang-2 and PCT levels were detected,and receiver operating characteristic(ROC)curve analysis was used to analyze their correlations with deterioration of sepsis AKI in all groups.Results Serum levels of sTREM-1,Ang-2 and PCT in patients with sepsis AKI were significantly higher than those in patients with sepsis non-AKI(P<0.01);levels of the above indexes after treatment were significantly decreased compared with those before treatment in sepsis AKI group,and the levels in deterioration subgroup were significantly higher than those in improvement subgroup(P<0.01).ROC curve analysis showed that area under curve(AUC)values of showing correlations among serum sTREM-1,Ang-2 and PCT with deterioration of sepsis AKI were 0.76,0.73 and 0.81 respectively.Conclusion The higher levels of sTREM-1,Ang-2 and PCT in patients with sepsis complicated by early acute kidney injury are closely related to poor prognosis of patients.
作者
梁维
赵静
冯玲
何志婷
LIANG Wei;ZHAO Jing;FENG Ling;HE Zhi-ting(Department of Nephrology,the Ninth Hospital of Xi'an,Xi'an 710054,China)
出处
《解放军医药杂志》
CAS
2020年第1期60-63,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
陕西省自然科学基础研究项目(2014JQ3100)
西安市卫生局基金资助项目(J201601001)
